Evaluation of the Safety and Immunogenicity of a Live Attenuated Human Metapneumovirus Vaccine

Completed · Phase 1 · Has a placebo group

Conditions studied: Metapneumovirus

In brief

People who are infected with human metapneumovirus (HMPV) may develop upper and lower respiratory illnesses. Children are particularly sensitive to HMPV infection. This study will evaluate the safety and immune response of an HMPV vaccine in healthy adults, HMPV-seropositive children, and HMPV-seronegative infants and children.

Key facts

Study ID

NCT01255410

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

60

Starts

2011-01-01

Expected to finish

2015-01-01

Last updated by the study team

2015-12-15

Who can join

Age: 1 and older, up to 49. Sex: any. Healthy volunteers: accepted.

Where it is running

• Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health — Baltimore, Maryland, United States
• Seattle Children's Hospital — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.